WO2020128967A3 - Efinopegdutide for use in the treatment of severe non-diabetic obesity - Google Patents
Efinopegdutide for use in the treatment of severe non-diabetic obesity Download PDFInfo
- Publication number
- WO2020128967A3 WO2020128967A3 PCT/IB2019/061125 IB2019061125W WO2020128967A3 WO 2020128967 A3 WO2020128967 A3 WO 2020128967A3 IB 2019061125 W IB2019061125 W IB 2019061125W WO 2020128967 A3 WO2020128967 A3 WO 2020128967A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- oxyntomodulin derivative
- efinopegdutide
- treatment
- severe non
- diabetic obesity
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Obesity (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Abstract
Disclosed herein are methods of treating severe non-diabetic obesity with a fixed dose or multiple ascending dose of an oxyntomodulin derivative conjugate, wherein the oxyntomodulin derivative conjugate comprises an oxyntomodulin derivative comprising the amino acid sequence of SEQ ID NO: 2 and having a ring formation between residues 16 and 20; an IgG4 Fc region; and a polyethylene glycol, wherein the polyethylene glycol covalently links the oxyntomodulin derivative and the IgG4 Fc region.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862782035P | 2018-12-19 | 2018-12-19 | |
US62/782,035 | 2018-12-19 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2020128967A2 WO2020128967A2 (en) | 2020-06-25 |
WO2020128967A3 true WO2020128967A3 (en) | 2020-07-30 |
Family
ID=69167868
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2019/061125 WO2020128967A2 (en) | 2018-12-19 | 2019-12-19 | Methods of treating severe non-diabetic obesity |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2020128967A2 (en) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012173422A1 (en) * | 2011-06-17 | 2012-12-20 | Hanmi Science Co., Ltd. | A conjugate comprising oxyntomodulin and an immunoglobulin fragment, and use thereof |
WO2014017843A1 (en) * | 2012-07-25 | 2014-01-30 | Hanmi Pharm. Co., Ltd. | Composition for treating hyperlipidemia comprising oxyntomodulin derivative |
WO2014073845A1 (en) * | 2012-11-06 | 2014-05-15 | Hanmi Pharm. Co., Ltd. | A composition for treating diabetes or diabesity comprising oxyntomodulin analog |
WO2016043533A1 (en) * | 2014-09-16 | 2016-03-24 | Hanmi Pharm. Co., Ltd. | Use of a long acting glp-1/glucagon receptor dual agonist for the treatment of non-alcoholic fatty liver disease |
WO2019171352A2 (en) * | 2018-03-08 | 2019-09-12 | Janssen Pharmaceutica Nv | Methods of treating severe non-diabetic obesity |
-
2019
- 2019-12-19 WO PCT/IB2019/061125 patent/WO2020128967A2/en active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012173422A1 (en) * | 2011-06-17 | 2012-12-20 | Hanmi Science Co., Ltd. | A conjugate comprising oxyntomodulin and an immunoglobulin fragment, and use thereof |
WO2014017843A1 (en) * | 2012-07-25 | 2014-01-30 | Hanmi Pharm. Co., Ltd. | Composition for treating hyperlipidemia comprising oxyntomodulin derivative |
WO2014073845A1 (en) * | 2012-11-06 | 2014-05-15 | Hanmi Pharm. Co., Ltd. | A composition for treating diabetes or diabesity comprising oxyntomodulin analog |
WO2016043533A1 (en) * | 2014-09-16 | 2016-03-24 | Hanmi Pharm. Co., Ltd. | Use of a long acting glp-1/glucagon receptor dual agonist for the treatment of non-alcoholic fatty liver disease |
WO2019171352A2 (en) * | 2018-03-08 | 2019-09-12 | Janssen Pharmaceutica Nv | Methods of treating severe non-diabetic obesity |
Non-Patent Citations (11)
Title |
---|
ANONYMOUS: "2017-003616-39: A Randomized, Double-blind Placebo-controlled and Open-label Active-controlled, Parallel-group, Multicenter, Dose-ranging Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Non-diabetic Severely Obese Subjects", 13 March 2018 (2018-03-13), pages 1 - 5, XP055612057, Retrieved from the Internet <URL:https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-003616-39/SE> [retrieved on 20190809] * |
ANONYMOUS: "Disposicion N° 05458", 17 July 2017 (2017-07-17), pages 1 - 8, XP055612052, Retrieved from the Internet <URL:http://www.anmat.gov.ar/boletin_anmat/mayo_2017/Dispo_5458-17.pdf> [retrieved on 20190809] * |
ANONYMOUS: "Efinopegdutide", REGISTRY, CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US, 8 January 2017 (2017-01-08), XP002793492 * |
ANONYMOUS: "HM 12525A - AdisInsight", 14 October 2017 (2017-10-14), pages 1 - 4, XP055612030, Retrieved from the Internet <URL:http://web.archive.org/web/20171014193308/https://adisinsight.springer.com/drugs/800040692> [retrieved on 20190809] * |
ANONYMOUS: "International Nonproprietary Names for Pharmaceutical Substances (INN)", WHO DRUG INFORMATION, vol. 31, no. 4, 19 January 2017 (2017-01-19), pages 635 - 754, XP055612042 * |
ANONYMOUS: "NCT03486392: A Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Non-diabetic Severely Obese Participants", 30 March 2018 (2018-03-30), pages 1 - 9, XP055612060, Retrieved from the Internet <URL:https://clinicaltrials.gov/ct2/history/NCT03486392?V_1=View#StudyPageTop> [retrieved on 20190809] * |
J KANG ET AL: "791: The ultra-long acting LAPSGLP/GCGdual agonist,HM12525A, demonstrated safety and prolonged pharmacokinetics in healthy volunteers: a phase 1 first-in-human study", ABSTRACTS OF 51ST EASD ANNUAL MEETING, vol. 58, 1 September 2015 (2015-09-01), pages S380 - S381, XP055611972 * |
JAHOON KANG ET AL: "The ultra-long acting LAPS GLP/GCG dual agonist, HM12525A, demonstrated safety and prolonged pharmacokinetics in healthy volunteers: a phase 1 first-in-human study PS-069-791 REFERENCES", 23 September 2015 (2015-09-23), pages 1 - 2, XP055612020, Retrieved from the Internet <URL:http://www.hanmipharm.com/ehanmi/img/rnd/2015_EASD_(HM12525A).pdf> [retrieved on 20190809] * |
JI-HEE HA ET AL: "Immunoglobulin Fc Heterodimer Platform Technology: From Design to Applications in Therapeutic Antibodies and Proteins", FRONTIERS IN IMMUNOLOGY, vol. 7, 6 October 2016 (2016-10-06), pages 1 - 16, XP055377975, DOI: 10.3389/fimmu.2016.00394 * |
S JUNG ET AL: "Potent weight loss mechanism and improvement of NASH by the long-acting GLP-1/glucagon receptor dual agonist HM12525A", ABSTRACTS OF 51ST EASD ANNUAL MEETING, vol. 58, 1 September 2015 (2015-09-01), pages S380 - S381, XP055611969, DOI: 10.1007/s00125-015-3687-4 * |
SY JUNG ET AL: "A Novel Long-Acting GLP-1/Glucagon Dual Receptor Agonist: Potent Weight Loss Mechanism and Improvement of NASH by HM12525A", 75TH ANNUAL SCIENTIFIC SESSIONS OF THE AMERICAN DIABETES ASSOCIATION, 6 June 2015 (2015-06-06), pages 1, XP055611892 * |
Also Published As
Publication number | Publication date |
---|---|
WO2020128967A2 (en) | 2020-06-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2019171352A3 (en) | Methods of treating severe non-diabetic obesity | |
NZ708105A (en) | A composition for treating diabetes or diabesity comprising oxyntomodulin analog | |
NZ705384A (en) | Composition for treating hyperlipidemia comprising oxyntomodulin derivative | |
WO2007030266A3 (en) | Nitric oxide-releasing polymers derived from modified polyimines | |
WO2001014424A3 (en) | Human ctla-4 antibodies and their uses | |
WO2007024501A3 (en) | Nitric oxide-releasing biodegradable polymers useful as medical devices and coatings therefore | |
MX340014B (en) | Pharmaceutical composition for treatment and/or prevention of cancer. | |
MX2012009000A (en) | Pharmaceutical composition for treatment and/or prevention of cancer. | |
EP3173480A3 (en) | Cancer antigen-specific t-cell receptor gene, peptide encoded by the gene, and use of them | |
WO2007043048A3 (en) | Self-assembled fmoc-ff hydrogels | |
WO2011149964A3 (en) | Methods for treating or preventing vascular graft failure | |
WO2007019865A3 (en) | Therapy with cd4 binding peptides and radiation | |
WO2007097903A3 (en) | Hiv fusion inhibitor peptides with improved biological properties | |
RU2013126581A (en) | STREPTokinase MUTANTS AND THEIR COVALENT MODIFIED FORMS | |
WO2007024686A3 (en) | Highly cross-linked and wear-resistant polyethylene prepared below the melt | |
WO2022020652A3 (en) | Stapled peptides and methods thereof | |
WO2020087057A8 (en) | Macromolecular prodrug-based thermosensitive injectable gel as a novel drug delivery platform | |
EP4269562A3 (en) | Antigen binding molecules and methods of use thereof | |
PH12021550082A1 (en) | Fcrn antibody compositions | |
WO2021207433A3 (en) | Epitopes of sars-cov-2 neutralizing antibodies | |
MX2020011453A (en) | Combinations for treating cancer. | |
WO2016092555A3 (en) | Isolated phosphotriesterase polypeptides, polynucleotides encoding same and uses thereof in treating or preventing organophosphate exposure associated damage | |
WO2020128967A3 (en) | Efinopegdutide for use in the treatment of severe non-diabetic obesity | |
WO2022010939A3 (en) | Peptides and methods of using the same | |
PL374433A1 (en) | Method for binding particulate, water-absorbing, acid group-containing polymers to a base material |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 19836838 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 19836838 Country of ref document: EP Kind code of ref document: A2 |